Skip to main content
PRQR
NASDAQ Life Sciences

ProQR's Q2 2026 Update: Cash Runway to Mid-2028 and a Pipeline of Clinical Milestones

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$1.91
Mkt Cap
$256.843M
52W Low
$1.33
52W High
$3.1
52W Position info
44% above low
Off High info
38% below high
Rel. Volume info
0.4× avg
Market data snapshot near publication time

PRQR sits 44% above its 52-week low of $1.33.

Summary

ProQR reported Q2 2026 financial results with a net loss of €8.7M and cash of €117.1M, supporting runway through mid-2028. Updates on the Axiomer RNA editing pipeline were also provided, including upcoming data readouts for AX-0810 and AX-0811.


Key Events · Earnings and Guidance · PRQR

  • Q2 2026 Financial Results

    Net loss narrowed to €8.7M (€0.08/share) from €12.2M (€0.12/share) in Q2 2025, while revenue rose to €8.8M from €3.8M.

  • Cash Runway Extended

    Cash and cash equivalents reached €117.1M as of June 30, 2026, up from €92.4M at year-end 2025, supporting runway through mid-2028.

  • AX-0811 CTA Submitted

    A Clinical Trial Application was submitted to the EMA in July 2026 for a Phase 1 trial of AX-0811, a next-generation NTCP-targeting EON.

  • Upcoming Clinical Milestones

    AX-0810 full Phase 1 data by year-end 2026; AX-0811 initial data by year-end 2026; biliary atresia IIT initiation and initial data in H1 2027; AX-0422 initial data in H1 2027; AX-2911 FIH IIT in H1 2027.


Analysis · PRQR · Life Sciences

The second quarter of 2026 brought a narrower net loss and a stronger cash position of €117.1M, extending the runway to mid-2028. A detailed pipeline update accompanied the results, including the CTA submission for AX-0811 and multiple data readouts expected over the next 18 months. For investors tracking clinical progress and financial stability, this is a meaningful update.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, PRQR was trading at $1.91 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $256.8M. The 52-week trading range was $1.33 to $3.10. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PRQR - Latest Insights

PRQR
Nov 12, 2026, 7:00 AM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $1.26
Real-time Price: $1.23 info
Change: -$0.030 (-2%) info
Market Cap: $166.523M info
PRQR
Nov 12, 2026, 7:00 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.26
Real-time Price: $1.23 info
Change: -$0.030 (-2%) info
Market Cap: $166.523M info
PRQR
Sep 09, 2026, 8:00 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $2.05
Real-time Price: $1.23 info
Change: -$0.820 (-40%) info
Market Cap: $166.523M info
PRQR
Aug 13, 2026, 7:11 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $1.91
Real-time Price: $1.23 info
Change: -$0.680 (-36%) info
Market Cap: $166.523M info
PRQR
Aug 13, 2026, 7:00 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $1.85
Real-time Price: $1.23 info
Change: -$0.6208 (-34%) info
Market Cap: $166.523M info